Paul-Georg Majev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul-Georg Majev has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Backialakshmi Dharmalingam
Max Planck Institute for Molecular Biomedicine, Department of Tissue Morphogenesis, Münster, Germany
2 shared publications - Kishor Kumar Sivaraj
Max Planck Institute for Molecular Biomedicine, Münster, Germany
2 shared publications - Ralf Heinrich Adams
Max Planck Institute for Molecular Biomedicine
2 shared publications Silke Schröder
Department of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine, Münster, Germany
2 shared publicationsAlfred Nordheim
Department of Molecular Biology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany
1 shared publicationBella Banjanin
Department of Developmental Biology, Erasmus University Medical Center, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 29 July 2024
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (8) , 951-969
Endothelial LATS2 is a suppressor of bone marrow fibrosis
Myelofibrosis and osteosclerosis are fibrotic diseases disrupting bone marrow function that occur in various leukemias but also in response to non-malignant alterations in hematopoietic cells. Here we show that endothelial cell–specific inactivation of the Lats2 gene, encoding Hippo kinase large tumor suppressor kinase 2, or overexpression of the downstream effector YAP1 induce myofibroblast formation and lead to extensive fibrosis and osteosclerosis, which impair bone marrow function and cause extramedullary hematopoiesis in the spleen. Mechanistically, loss of LATS2 induces endothelial-to-mesenchymal transition, resulting in increased expression of extracellular matrix and secreted signaling molecules. Changes in endothelial cells involve increased expression of serum response factor target genes, and, strikingly, major aspects of the LATS2 mutant phenotype are rescued by inactivation of the Srf gene. These findings identify the endothelium as a driver of bone marrow fibrosis, which improves understanding of myelofibrotic and osteosclerotic diseases, for which drug therapies are currently lacking.
- 29 July 2024
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (8) , 951-969
Open AccessEndothelial LATS2 is a suppressor of bone marrow fibrosis
Myelofibrosis and osteosclerosis are fibrotic diseases disrupting bone marrow function that occur in various leukemias but also in response to non-malignant alterations in hematopoietic cells. Here we show that endothelial cell–specific inactivation of the Lats2 gene, encoding Hippo kinase large tumor suppressor kinase 2, or overexpression of the downstream effector YAP1 induce myofibroblast formation and lead to extensive fibrosis and osteosclerosis, which impair bone marrow function and cause extramedullary hematopoiesis in the spleen. Mechanistically, loss of LATS2 induces endothelial-to-mesenchymal transition, resulting in increased expression of extracellular matrix and secreted signaling molecules. Changes in endothelial cells involve increased expression of serum response factor target genes, and, strikingly, major aspects of the LATS2 mutant phenotype are rescued by inactivation of the Srf gene. These findings identify the endothelium as a driver of bone marrow fibrosis, which improves understanding of myelofibrotic and osteosclerotic diseases, for which drug therapies are currently lacking.
- Open Access
- 28 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Mesenchymal stromal cell-derived septoclasts resorb cartilage during developmental ossification and fracture healing
Developmental osteogenesis, physiological bone remodelling and fracture healing require removal of matrix and cellular debris. Osteoclasts generated by the fusion of circulating monocytes degrade bone, whereas the identity of the cells responsible for cartilage resorption is a long-standing and controversial question. Here we show that matrix degradation and chondrocyte phagocytosis are mediated by fatty acid binding protein 5-expressing cells representing septoclasts, which have a mesenchymal origin and are not derived from haematopoietic cells. The Notch ligand Delta-like 4, provided by endothelial cells, is necessary for septoclast specification and developmental bone growth. Consistent with the termination of growth, septoclasts disappear in adult and ageing bone, but re-emerge in association with growing vessels during fracture healing. We propose that cartilage degradation is mediated by rare, specialized cells distinct from osteoclasts. Our findings have implications for fracture healing, which is frequently impaired in aging humans.
- 28 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Open AccessMesenchymal stromal cell-derived septoclasts resorb cartilage during developmental ossification and fracture healing
Developmental osteogenesis, physiological bone remodelling and fracture healing require removal of matrix and cellular debris. Osteoclasts generated by the fusion of circulating monocytes degrade bone, whereas the identity of the cells responsible for cartilage resorption is a long-standing and controversial question. Here we show that matrix degradation and chondrocyte phagocytosis are mediated by fatty acid binding protein 5-expressing cells representing septoclasts, which have a mesenchymal origin and are not derived from haematopoietic cells. The Notch ligand Delta-like 4, provided by endothelial cells, is necessary for septoclast specification and developmental bone growth. Consistent with the termination of growth, septoclasts disappear in adult and ageing bone, but re-emerge in association with growing vessels during fracture healing. We propose that cartilage degradation is mediated by rare, specialized cells distinct from osteoclasts. Our findings have implications for fracture healing, which is frequently impaired in aging humans.